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Abstract The main debate in the treatment of Phenylke-
tonuria (PKU) is whether adult patients need the strict
phenylalanine (Phe)-restricted diet. Physicians and
patients lack evidence-based guidelines to help them
make well-informed choices. We have carried out the
first randomised double-blind placebo-controlled trial
into the effects of short-term elevation of Phe levels on
neuropsychological functions and mood of adults with
PKU. Nine continuously treated adults with PKU
underwent two 4-week supplementation periods: one
with Phe, mimicking normal dietary intake, and one
with placebo in randomly allocated order via a random-
isation coding list in a double-blind cross-over design. A
set of neuropsychological tests (Amsterdam Neuropsy-
chological Tasks) was administered at the end of each
study period. In addition, patients and for each patient a
friend or relative, completed weekly Profile of Mood
States (POMS) questionnaires, evaluating the patients’
mood. Phe levels were measured twice weekly. Mean
plasma Phe levels were significantly higher during Phe
supplementation compared with placebo (p=0.008). Neu-
ropsychological tests demonstrated an impairment in
sustained attention during Phe supplementation (p=
0.029). Both patients and their friend or relative reported
lower scores on the POMS questionnaires during Phe
supplementation (p=0.017 and p=0.040, respectively).
High plasma Phe levels have a direct negative effect on
both sustained attention and on mood in adult patients
with PKU. A Phe-restricted “diet for life” might be an
advisable option for many.
Introduction
Phenylketonuria (PKU; OMIM 261600) is an autosomal
recessive inborn error of metabolism caused by a
deficiency of the enzyme phenylalanine hydroxylase
(PAH; EC 1.14.16.1), which catalyses the conversion of
the amino acid phenylalanine (Phe) into tyrosine. PKU is
a pan-ethnic disease with an estimated birth prevalence
varying from 1:2,500 to 1:125,000 (Scriver et al. 2008),
and it has been diagnosed in approximately 13,000 people
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DOI 10.1007/s10545-010-9253-9in the U.S. and 50,000 people worldwide. The enzyme
deficiency results in a high concentration of Phe which is
neurotoxic, particularly during the first years of life
(Albrecht et al. 2009). Untreated PKU results in severe
intellectual disability and neurological sequelae (Scriver et
al. 2008). Since the 1960s, these complications can be
prevented by detection through newborn screening
followed by dietary treatment consisting of a restriction
of Phe intake by a protein-restricted diet and supplemen-
tation of all amino acids but Phe. However, a highly
controversial issue in the treatment of PKU is whether a
strict dietary control of Phe levels is still necessary in
adults. With the first PKU patients detected by newborn
screening now in their 40s, there is a rapidly growing
cohort of adults with early and continuously treated PKU
for whom evidence-based treatment guidelines are lack-
ing. Current dietary guidelines for adults vary widely (Van
Spronsen et al. 2009), and in some countries relaxation of
the diet in adolescence is common practice (Schweitzer-
Krantz and Burgard 2000). Dietary relaxation for adults
might be considered safe on the basis of the observation
that discontinuation of the diet does not cause a major
decrease in IQ in adults (Burgard 2000). However, mild
cognitive sequelae including executive function deficits
have been reported (Christ et al. 2010a). These deficits,
associated with concurrent high Phe levels, have been
observed in both children and adults (Huijbregts et al.
2002b, c; Schmidt et al. 1994). In other disorders,
impairments in executive function have been correlated
with deficits in social relationships and communication
skills (Beauchamp and Anderson 2010). Self reports by
PKU patients as well as experiences of treating physicians,
including ourselves, suggest that high Phe levels may in
some cases result in irritability, impacting on adaptive
social skills (www.pku.com, www.childrensmemorial.org/
depts/genetics/pku.aspx) However, the effect of high Phe
levels on mood in continuously treated adults with PKU
has never been studied.
In order to improve guidelines on dietary therapy for adults
with PKU, the consequences ofelevated Phe levels mimicking
a full relaxation of the diet need to be studied prospectively. To
this end, we performed a double-blind placebo-controlled
crossover Phe-loading study in early and continuously treated
adults with PKU focusing on the impact of high Phe levels on
executive functioning as well as on mood.
Patients and methods
Patients
Patients were recruited via treating physicians in the
Academic Medical Center Amsterdam (AMC), the Univer-
sity Medical Centres of Groningen, Maastricht, and
Nijmegen (The Netherlands), and the Centrum Pinocchio,
Diepenbeek (Belgium). Patients were enrolled in the study
between December 2007 and December 2008. Patients with
PKU aged≥18 years, who were diagnosed by newborn
screening and continuously treated and had a mean
plasma Phe level <1,100 μmol/L in the year prior to the
start of the study, were eligible for inclusion. Exclusion
criteria included mental or legal incapacitation, drug or
alcohol misuse, a diagnosis of neurological disease,
psychiatric illness, lack of fluency in Dutch and inability
to comply with study procedures. Additional exclusion
criteria for females were pregnancy or the wish to
become pregnant within a year of the start of the study.
Patients signed an institutionally approved informed
consent prior to enrolment. Approval for this study
was granted by the Ethical Committee of the AMC,
Amsterdam. The trial was registered with The Netherlands
National Trial Register (NTR # 1056) before recruiting of
patients.
Procedure
Patients were instructed to continue their prescribed natural
protein-restricted diet and supplementation of amino acids
throughout the study. To determine intake of Phe, daily
consumption of natural protein was evaluated in a 3-day
dietary record by a dietician prior to the start of the study.
The trial had a double-blind cross-over design. Patients
were randomly assigned to one of the two groups, starting
eitherwithplacebo-containingcapsulesorwithPhe-containing
capsules. After 4 weeks, patients crossed over to the alternative
treatment arm.
During the period in which Phe capsules were con-
sumed, each patient received an individually calculated
amount of Phe, taking into account their dietary Phe intake,
to reach the total Phe intake likely to be consumed by a
healthy adult of the same sex and weight and thus
mimicking the condition of being fully ‘off diet’. The
protein intake of healthy Dutch adults is higher in men than
in women. Average Phe intakes aimed at were: 4,500 mg
per day (mpd) for male patients between 60 and ≤95 kg,
4,000 mpd <60 kg, 5,000 mpd >95 kg, 3,000 mpd for
female patients between 50 and ≤85 kg, 2,500 mpd <50 kg,
and 3,500 mpd >85 kg.
For placebo and Phe, capsules were identical in
appearance. Patients had the choice to swallow the capsules
whole or to open the capsules and add the content to their
amino acid mixture. Patients took 2–8 capsules a day
(average 5 capsules), divided over 3 doses. To monitor the
compliance with the capsules, patients recorded the intake
of the capsules in a diary. Between the two study periods,
there was a washout period of at least 4 weeks in which
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Randomisation and masking
An independent data manager rendered a randomisation
coding list. A non-deterministic version of the minimisation
method (Pocock and Simon 1975) was used to balance
treatment arms. No stratification factors were used. This
list, which contained numbers linked to the patients by the
study physician, and allocated treatment assignments, was
sent to the pharmaceutical company which used it to
prepare the capsules. All patients and investigators were
masked to treatment assignment.
Capsules were prepared and coded by Nutricia Liver-
pool (Liverpool, UK) and distributed to the patients by the
study physician (A.H.) at the start of each study period.
Capsules were packed in identical tubs, labelled with patient
number, phase number, and a three-letter code and barcode
indicating placebo or Phe. In order to prevent identification
and comparison by the patients, three different three-letter
codes were used for both Phe- and placebo-containing
capsules.
Biochemical monitoring
Phe levels in bloodspots were measured twice weekly
during the two 4-week study periods and during the week
before each study period. This was achieved using tandem
mass spectrometry (standard neutral loss method). Results
were not disclosed to the investigators until data were ready
for analysis.
Neuropsychological measures
The primary outcome measure was the change in neuro-
psychological functioning between the placebo and the Phe
supplementation periods.
The Amsterdam Neuropsychological Tasks (ANT)
program (De Sonneville 2005, 2009) was used to evaluate
neuropsychological function. ANT has successfully been
used to determine neurocognitive deficit profiles for
various clinical conditions, including PKU (Burgard et
al. 1997; Huijbregts et al. 2002b). Various ANT paradigms
have been shown to be sensitive to changes in neuropsy-
chological functioning following dietary interventions in
children (Huijbregts et al. 2002b) and adults (Schmidt et
al. 1994) with PKU. These tasks were selected to draw out
a neuropsychological profile associated with Phe-loading.
Measures included simple reaction time, sustained atten-
tion, visuospatial processing, working memory capacity,
inhibition and set shifting and visuomotor control (random
pursuit, circle tracing). Detailed task descriptions can be
found elsewhere (De Sonneville et al. 2002; Pietz et al.
1993). Based on earlier studies (Huijbregts et al. 2003;
Pietz et al. 1993), Phe-loading was expected to unfavour-
ably affect task performance on all tasks except on simple
reaction time and simple visuomotor control (circle
tracing). Neuropsychological assessment was performed
four times: twice before the first study period in order to
minimise learning effects which may occur after repeated
administration of neuropsychological tests and on the last
day of each 4-week study period. The results of the latter
two assessments were subjected to statistical analysis.
Tasks were administered using a computer. The input
device for the patients’ responses was a standard mouse
with symmetrical buttons. Prior to task administration,
patients practised until the tasks were understood.
IQ was estimated using a 4-subtests short form of the
Wechsler Adult Intelligence Scale-Revised (WAIS-III;
Wechsler 1981) consisting of vocabulary, picture completion,
block design and similarities.
In all patients, neuropsychological tests and IQ tests
were performed by one investigator (A.H.).
Clinical measures
The secondary outcome measure was the change in mood
state of the patients, which was evaluated by the standardised
“Profile of Mood States” (POMSr) questionnaire (revised
version) (Wald and Mellenbergh 1990). This questionnaire is
designed to provide data on five categories of mood states:
tension, depression, anger, vigour, fatigue (mood types). The
questionnaire was completed weekly during each 4-week
study period by the patients and by a significant other of
each patient (spouse, friend or close colleague) reporting on
the patient’sm o o d .
Statistical analysis
Task performance data of the ANT, obtained at the end of the
two study periods, were pooled across groups per condition
(placebo, Phe). Repeated measures analysis of variance
(ANOVA), with experimental condition (placebo vs Phe-
loading) as within-subject factor was used to test changes in
neuropsychological outcome. Additional within-subject fac-
tors, when relevant, were entered to test the interactions of
interventionwith task manipulations (forexample:increasein
memory load, in visuospatial complexity, etc.). Separate runs
were made with reaction time and number of errors as a
dependent variable.
Similarly, scale scores for the five categories of mood
states of the POMSr were computed per type of observer
(patient and friend or relative) and the results were pooled
across groups per experimental condition. Before statistical
analysis, an average score of all patients on the five
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study periods. To test whether mood differed between
treatment conditions and whether differences were mood
type-dependent, scores were subjected to repeated measures
analyses ANOVA with experimental condition and mood
type as within-subject factor. Separate runs were made for
each observer type. Effect sizes were estimated by means of
partial eta squared (ηp
2). Large effects correspond with
ηp
2≥0.14, moderate effects with ηp
2≥0.06 and ηp
2<0.14,
and weak effects with ηp
2<0.06 (Cohen 1988).
Prior to analysis, the vigour scale scores have been
recoded to the effect that higher scores are associated with
an unfavourable outcome (less vigour), in the same way
that higher scores denote more tension, more depression,
more anger and more fatigue. For the analysis of the effect
of the loading condition on mood and the analysis of the
neuropsychological task result, alpha was set at 0.05. Post-
hoc power analyses was applied to all trend and non-
significant results that were interpreted as meaningful on
the basis of the estimated effect sizes.
Results
Patients
On the basis of inclusion and exclusion criteria and
expected willingness to participate at the discretion of the
treating physician, 129 patients were eligible to participate
in this study. Of them, 12 patients agreed to participate.
Fear of effects of elevated Phe levels, the time demanded
by the study and the fact that most patients had already
participated in multiple previous studies on PKU were the
most prominent reasons for not participating. One patient
was excluded before the start of the study because of a
co-existing illness possibly affecting cognition. Between
December 2007 and December 2008, patients were rando-
mised; the study was completed in April 2009. Patients
were randomly allocated to one of the treatment arms: either
Phe-loading–placebo or placebo–Phe-loading. One patient
withdrew before the start of the investigations because of
pressure at work and one patient withdrew after the first
neuropsychological test because his partner feared elevated-
Phe-related negative changes in his behaviour. All the
remaining 9 patients completed the study. Table 1 shows the
patients’ baseline characteristics, including pre-study dietary
Phe intake and mean blood Phe value in the year prior to the
study, reflecting a very variable individual Phe tolerance in
this cohort that includes classical as well as mild PKU
patients. Compliance with taking the capsules was 99.6% in
the first and 99.1% in the second study period.
IQ
WAIS IQs, estimated from the 4-subtest short form of the
Wechsler Adult Intelligence Scale-Revised were within
normal range (M=97.22, range 83–117), (Table 1), although
slightly below the population mean, which may be due to
sampling error in this small sample size but is also consistent
with previous studies (Pietz et al. 1998; Schmidt et al. 1996).
Phe levels
Mean (standard deviation) blood Phe value was
1,259 μmol/L (±332) in the Phe-loading phase and
709 μmol/L (±322) in the placebo phase, which was
significantly different (Wilcoxon signed-ranks test p=
0.008) (Fig. 1). In the week prior to the second study
period, after a washout of at least 4 weeks, the mean Phe
level was 702 umol/L (±389), which is comparable to the
mean Phe level in the week prior to the first study period of
790 umol/L (±332).
Mood
Figure 2 shows the mean scale scores per observer (self,
friend or relative) on the different subscales of the
POMSr during Phe-loading or placebo. Self-reported
Patient Gender Age (years) Weight (kg) IQ Total pre-study Phe
intake (mg)
Mean pre-study blood
Phe value (μmol/L)
1 F 20 65 105 2,350 560
2 M 28 73 83 1,175 784
3 F 26 80 102 1,750 427
4 F 23 50 87 1,595 978
5 M 34 75 105 1,470 936
6 F 20 60 117 1,095 346
7 F 22 67 83 580 635
8 F 19 78 86 535 388
9 M 20 94 107 810 786
Table 1 Baseline characteristics
168 J Inherit Metab Dis (2011) 34:165–171mood stateswere significantly less favourable during the Phe-
loading period compared to the placebo period (F1,8 =9 . 0 3 ,
p=0.017, ηp
2=0.53). Post-hoc testing revealed patients to
feel more depressed (trend, p=0.097, ηp
2=0.31, power=
0.38), more fatigued (p=0.021, ηp
2=0.51), and less vigorous
(p=0.006, ηp
2=0.64). Similarities were found for the report
by a friend or relative. Overall mood was significantly less
favourable during Phe-loading (F1,8 =6 . 0 2 ,p=0.040, ηp
2=
0.43, power=0.58] and post-hoc testing showed that the
friend or relative reported more depression (trend, p=0.057,
ηp
2=0.38, power=0.50) and more fatigue (trend, p=0.069,
ηp
2=0.36, power=0.46) as well. Differences were that the
friend or relative reported more anger (trend, p=0.052,ηp
2=
0.39, power=0.52) and did not report a less vigorous mood
state. One friend or relative lost the questionnaires completed
during the placebo phase. The missing scale scores for this
patient were substituted by the mean scale scores, obtained
during the placebo phase, of the remaining group of the
friends or relatives.
Neuropsychological profile
Statistical analysis of the neuropsychological performance
data showed that Phe-loading resulted in a significant larger
fluctuation in tempo during sustained attention compared to
the placebo supplementation (F1,8 =7 . 0 2 ,p=0.029, ηp
2=
0.47, power=0.64). On all other measures of neuropsycho-
logical function, the effects of Phe-loading were not
significant, although differences on two following tasks
were accompanied by large effect sizes: Phe-loading resulted
in slower reaction times (ηp
2=0.20, power=0.25) in the
inhibition and set shifting task and in slower recognition of
complex patterns (ηp
2=0.16) in the visuospatial pattern
recognition task.
Discussion
This is the first double-blind, randomised, placebo-
controlled cross over trial designed to investigate the effects
of a fully normalised Phe intake on both executive function
and mood in adults with PKU.
We demonstrated that elevated Phe levels are associated
with a negative effect on sustained attention as well as on
the mood of the patients. Indeed, the high Phe levels
impaired sustained attention by increasing the fluctuation in
speed, which has been previously reported (Huijbregts et al.
2002c; Schmidt et al. 1994). Hypothetically, the impairment
of sustained attention might have consequences for the
daily functioning of patients with PKU. Insufficient
attention to tasks can result in ‘slips’ of action or everyday
attention failures as automatic unintended action sequences
are triggered inappropriately. Such slips can arise from
deficits in sustained attention which have been reported
to occur following frontal lobe and white matter damage
from very different causes (e.g. in traumatic brain injury)
(Robertson et al. 1997).
It is therefore interesting that white matter changes have
been demonstrated in patients with treated PKU (Pietz et al.
1998; Vermathen et al. 2007) and that the prefrontal cortex
is thought to play a role in the pathophysiology of the
neurological complications in PKU (Welsh 1996; Christ et
al. 2010b). Joseph and Dyer (2003) reported dopamine
depletion in the prefrontal cortex of a PKU mouse model,
which was thought to be caused by hypomyelinisation
leading to down-regulation of neurotransmitter production
(Joseph and Dyer 2003). Another cause for dopamine
depletion in patients with PKU may be the low levels of its
precursor tyrosine, caused by competition of high Phe
levels with the uptake of tyrosine across the blood–brain
barrier as both amino acids are transported by the same
neutral amino acid transporter (Welsh 1996). Dopaminergic
neurons that project on the prefrontal cortex are highly
sensitive to even small decreases in tyrosine (Tam and Roth
1997), and dopamine is believed to be involved in frontal
lobe functions, such as working memory, information
processing and attention (Nieoullon and Coquerel 2003).
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tracking, which is consistent with reports in the literature
(Huijbregts et al. 2003). PKU patients have deficits in tasks
requiring a high level of monitoring and manipulation
(Diamond et al. 1997; Huijbregts et al. 2002a, b). The
pursuit task consists of following a randomly moving object
and requires more concurrent planning and adaptation
compared to the tracking task. It might be expected for
PKU patients to have lower scores on the pursuit task,
which we did not find. One explanation might be that the
pursuit task and the baseline speed task have a much shorter
duration compared to the sustained attention task and are
not demanding enough.
In contrast with the other studies, we observed no
significant difference in performance on the inhibition, set
shifting and memory task (Huijbregts et al. 2002a; Pietz et
al. 1993). However, large effect sizes (ηp
2≥0.14) were seen
on reaction times in the inhibition and moderate effect sizes
on the set shifting task. A large and a moderate effects size
was also observed in the tasks on recognition of complex
patterns and visuospatial pattern recognition task, respec-
tively, suggesting an influence of high Phe levels.
I m p o r t a n t l y ,w er e p o r tf o rt h ef i r s tt i m eac l e a r
association between high blood Phe levels and poor mood
when compared with the placebo supplementation. Crucially,
this effect was reported by both patients and their friend or
relative, which would suggest that the migration to a more
negative mood is sufficiently severe for individuals to be self
aware of it.
The possible biochemical nature of this phenomenon
could be a lower level of brain serotonin. Like dopamine,
tryptophan as a precursor of serotonin competes with Phe
for transport across the blood–brain barrier (Hargreaves and
Pardridge 1988). Elevated Phe levels might reduce brain
tryptophan and consequently serotonin. Reduction in
serotonin levels might play a role in the pathogenesis of
psychological disorders, including depression, in patients
with PKU (Pietz et al. 1997). Thus, the altered mood states
due to high Phe levels as observed in our study may also be
caused by decreased serotonin levels.
We believe that persistent negative changes in mood
may ultimately impact stability in relationships and social
interactions and should therefore be avoided. Bik-
Multanowski et al. (2008) demonstrated a hampered
quality of life in 45% of a cohort of patients who were
off diet with high Phe levels. Resumption of the diet
improved the quality of life of most of these patients,
mostly in the domains of anxiety and depressiveness.
We recognise that a limitation of the present study is the
small number of participating patients. This may well have
prevented unfavourable effects of Phe-loading reaching
significance on inhibition and complex visuospatial pattern
processing, as these differences showed large effect sizes.
Future studies with a larger cohort of patients are warranted
to further explore our findings.
Finally, as only the effects of a relative short period of
high Phe levels were studied, we do not know if the
observed negative effects would remain in the long term or
if adaptive mechanisms may result in a normalisation of
mood and performance in patients with PKU who stop
following their prescribed diets.
In conclusion, we demonstrated that short-term high Phe
levels have a significant direct negative effect on mood and
neuropsychological performance in adult patients with
PKU. Patients should be educated that potential advantages
of going off diet should be balanced against a negative
influence on mood, in addition to the consequences of
attention failures. A Phe restricted “diet for life” might be
an advisable option for many.
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